The University of Washington
Dr. Matt Kaeberlein is an American biologist and biogerontologist best known for his research on evolutionarily conserved mechanisms of aging. He is currently a Professor of Pathology at the University of Washington in Seattle.
Kaeberlin attended Western Washington University as an undergraduate and received a B.S. in biochemistry and a B.A. in mathematics in 1997. He received his Ph.D. in Biology from MIT in 2002, advised by Leonard Guarente, and did his post-doctoral work with Stanley Fields in the Department of Genome Sciences at the University of Washington.
Kaeberlein is a Distinguished Visiting Professor of Biochemistry at the Aging Research Institute of Guangdong Medical College in Dongguan, China. He is also the co-Director of the University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging, the Director of SAGEWEB, and the founding Director of the Healthy Aging and Longevity Research Institute at the University of Washington. He is also a co-director of the Dog Aging Project.
AgeX / SENS Research Foundation
Dr. Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He is also VP of New Technology Discovery at AgeX Therapeutics, a biotechnology startup developing new therapies in the field of biomedical gerontology. In addition, he is Editor-in-Chief of Rejuvenation Research, the world's highest-impact peer-reviewed journal focused on intervention in aging. He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations.
Alex Aliper, Ph.D
Insilico Medicine
Alex Aliper is the Co-Founder and President of EMEA of Insilico Medicine, bioinformatics and deep learning company focused on reinventing drug discovery and biomarker development. He is actively engaged in the efforts of drug discovery and Artificial Intelligence units at Insilico Medicine and manages external collaborations with big pharma and biotech.
He holds a master's degree in bioengineering and bioinformatics and worked in the field of oncology and translational medicine at Bioinformatics Laboratory at the Federal Clinical Research Center for Pediatric Hematology, Oncology and Immunology, one of the largest children's cancer centers in the world. Co-founded Insilico in 2014. He holds a doctorate degree in biology.
Since 2012 he co-authored over 40 peer-reviewed research papers and his research interests lie in the fields of ageing, oncology, drug discovery, drug repurposing, deep learning and translational medicine. His recent research was focused primarily on in silico screening of geroprotectors and applications of generative adversarial networks and reinforcement learning for drug discovery and drug repurposing.
The European Research Institute for the Biology of Ageing (ERIBA)
Cornelis Calkhoven is a professor for gene regulation in ageing and age-related diseases at the University Medical Center of the University of Groningen and principal investigator at the European Research Institute for the Biology of Ageing (ERIBA). He studied biology and chemistry at the University of Groningen, where he also received his PhD-degree in 1996. As a Marie Curie Postdoctoral fellow, he then moved to the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, where in 2000 he was rewarded with a Helmholtz fellowship to start his own research group. At the MDC he identified factors and mRNA-regulatory elements that control translation of key factors in cellular differentiation and cancer. In 2005 he moved to the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) in Jena where he established a research program to study common regulatory mechanisms in ageing, metabolism and cancer. The main focus of the Calkhoven laboratory is on understanding the mechanisms of gene-regulation that are under control of the nutrient and energy sensitive mTORC1 signaling pathway and its involvement in health- and lifespan determination.
Cambridge Institute for Medical Research (CIMR)
Cornelis Calkhoven is a professor for gene regulation in ageing and age-related diseases at the University Medical Center of the University of Groningen and principal investigator at the European Research Institute for the Biology of Ageing (ERIBA). He studied biology and chemistry at the University of Groningen, where he also received his PhD-degree in 1996. As a Marie Curie Postdoctoral fellow, he then moved to the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, where in 2000 he was rewarded with a Helmholtz fellowship to start his own research group. At the MDC he identified factors and mRNA-regulatory elements that control translation of key factors in cellular differentiation and cancer. In 2005 he moved to the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) in Jena where he established a research program to study common regulatory mechanisms in ageing, metabolism and cancer. The main focus of the Calkhoven laboratory is on understanding the mechanisms of gene-regulation that are under control of the nutrient and energy sensitive mTORC1 signaling pathway and its involvement in health- and lifespan determination.
Max Planck Institute for Biology of Ageing
Dr. Antebi received his PhD in Biology from the Massachusetts Institute of Technology in 1992, and performed his post-doctoral studies at the Johns Hopkins University Baltimore, MD. From 1997 he worked as a Max Planck Independent Group Leader at the Max Planck institute for Molecular Genetics, Berlin, and from 2004 as an assistant and then associate professor with Baylor College of Medicine, Houston, Texas.
Dr. Antebi is currently one of the founding directors of the Max Planck Institute for Biology of Ageing, Cologne, which he has helped lead to become one of the most internationally recognized centers for ageing research in the world. He is also an honorary Professor through the University of Cologne, Center of Excellence Cluster on Cellular Stress Response and Age-associated Disease. Dr. Antebi's work has focused on endocrine and metabolic regulation of longevity in the small roundworm, Caenorhabditis elegans, an important model system for ageing research. Among his findings, he has discovered that components of developmental clocks can regulate animal life span, and found that small nucleoli are a cellular hallmark of longevity.
The University of Cologne
Professor Hoppe heads the research laboratory on ageing at the CECAD and Institute for Genetics, Cologne Germany. His group has identified regulatory mechanisms that coordinate protein degradation systems and the ageing process. Many of their studies use the nematode C.elegans as a model system to study physiological aspects of selective protein turnover by the ubiquitin proteasome system and autophagy in the context of ageing-associated processes. By manipulating rates of proteolysis, his team was able to prevent loss of central muscle proteins and therefore extend muscle activity, or to prevent protein aggregation and extend lifespan.
MRC Laboratory of Molecular Biology
Dr. Anne Bertolotti's research focuses on understanding and preventing the deposition of misfolded proteins in cells, a hallmark of numerous neurological diseases. Bertolotti has been a group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK since 2006. Prior to joining the LMB, she was an Associate Professor at Ecole Normale Superieure in Paris from 2001-2006. Bertolotti did her PhD training at the Institute of Genetics and Molecular and Cellular Biology (IGBMC) near Strasbourg, France and she did a postdoctoral research at the Skirball Institute of Biomolecular Medicine at NYU School of Medicine in New York.
Bertolotti was elected EMBO Young Investigator in 2005 and EMBO member in 2013. In 2014, she was awarded the Hooke Medal of the British Society for Cell Biology for her contributions to our understanding of abnormal protein folding. Bertolotti was elected Fellow of the UK Academy of Medical Sciences in 2017.
Pekka Katajisto, Ph.D
The University of Helsinki
Pekka Katajisto received his Ph.D. in 2009 from the University of Helsinki, for the work demonstrating that certain tumor suppressors can mediate their growth inhibitory function in a paracrine fashion. He then joined the laboratory of David Sabatini at the Whitehead Institute and MIT, to conduct postdoctoral research on cell-cell interactions in the context of stem cells and their surrounding niche. Currently, Dr. Katajisto runs two laboratories as the Associate Professor in Aging Biology, in HiLIFE, University of Helsinki, and in Department of Bioscience and Nutrition, Karolinska Institutet. His work focuses on the role of the niche-stem cell interaction and asymmetric cell division in aging. His discoveries include how the intestinal stem cell niche couples organismal nutrient status to the stem cell function, how alterations in nutrient sensing can result in secretion of novel aging factors, and that stem cells can segregate their organelles age-selectively during cell division. He is an ERC grantee, and the Director of the new Academy of Finland Center of Excellence in Stem cell metabolism.
Harvard Medical School
Vadim Gladyshev is a Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School, Director of the Center for Redox Medicine, and Associate Member of the Broad Institute. He obtained all his degrees from Moscow State University, followed by postdoc training at the National Institutes of Health and a first faculty position at the University of Nebraska. He seeks to understand the nature of aging and to define the principles of lifespan control. His lab applies high-throughput and computational approaches to achieve systems level understanding of the aging process and develop interventions that extend lifespan.
German Cancer Research Center (DKFZ)
Ana Martin-Villalba studied medicine in Murcia, Spain and Leeds, UK. She received her Ph.D. from the University of Heidelberg for investigating the role of death ligands in the ischemic brain. After receiving her Ph.D., she moved to the German Cancer Research Center (DKFZ) where she further worked on the strategies for CNS repair followed by stroke, spinal cord injuries or chronic CNS disorders, with a focus on the interaction of the CNS with the innate immune system and activation of endogenous stem cells. This work has also generated some understanding of how cancer stem cells contribute to tumor progression.
Ana was awarded the Paul Ehrlich and Ludwig Darmstaedter Prize, and the Heinz Maier-Leibnitz Prize and the Walther and Christine Richtzenhain Prize for the development of pro-regenerative and anti-cancer therapies. One of her findings has set the ground for a phase-II clinical trial of glioblastoma patient that increased the overall survival rate of a subgroup of glioblastoma-patients. She was awarded an ERC grant in 2018. Her research now centers on understanding stem cell behaviour in homeostasis and disease including CNS-injuries, aging and cancer.
The University of California
Danica Chen is an Associate Professor of Metabolic Biology, Nutritional Sciences & Toxicology at the University of California, Berkeley; a member of Berkeley Stem Cell Center, and a member of QB3 Consortium in Lifespan Extension. She was a Searle Scholar, an Ellison Scholar, a Kavli Fellow, and a Hellman Fellow. Dr. Chen received a Ph.D. in molecular and cell biology from the University of California and obtained postdoctoral training in biology at the Massachusetts Institute of Technology. Her research aims to understand the molecular and cellular mechanisms underlying aging-associated conditions and define which aspects of age-associated conditions are reversible. Recent studies from her lab have revealed mitochondrial stress as a cause of stem cell exhaustion and tissue degeneration during aging. Dr.Chen identified mitochondrial stress resistance programs that become dysregulated in aged stem cells, and demonstrated that these programs can be targeted to improve survival and regenerative capacity of aged stem cells. These findings give hope to targeting age-associated dysregulated cellular protective programs, such as the pathways regulated by NAD+- dependent enzymes sirtuins, to reverse stem cell aging, tissue degeneration and dysfunction.
Nir Barzilai, M.D.
Albert Einstein College of Medicine
The Institute for Aging Research
Dr. Barzilai is a chaired Professor of Medicine and Genetics and Director of the biggest Center in the world to study the Biology of Aging. He is the recipient of an NIH Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families of centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies. He is a recipient of numerous prestigious awards, including the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity award. He is leading the TAME (Targeting/Taming Aging with Metformin) multi central study to prove that concept that multi morbidities of aging can be delayed in humans and change the FDA indications to allow for next generation interventions. He is a founder of CohBar Inc. (now public company) and Medical Advisor for Life Biosciences. He is on the board of AFAR and a founding member of the Academy for Lifespan and Health span. He co-founded CohBar He has been featured in major papers, TV program and documentaries (TEDx and TEDMED) and has been consulting or presented the promise for targeting aging at The Singapore Prime Minister Office, several International Banks, The Vatican, Pepsico, Milkin Institute, The Economist and Wired Magazine.
Alex Zhavoronkov, Ph.D
Insilico Medicine
Dr. Alex Zhavoronkov is the founder and CEO of InSilico Medicine, a global leader in the next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. At InSilico, he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties and generation of synthetic biological and patient data. His group was the first to develop the deep-learned multi-modal predictors of age for drug discovery and biomarker development. He set up the R&D centers in 6 countries, including the United Kingdom, Korea, Russia, Hong Kong SAR, and Taiwan ROC.
Prior to founding InSilico Medicine, Dr. Zhavoronkov worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, and YLabs.AI and established the AgeNet.net competitions and Diversity.AI initiatives. He is co-founder and CSO of the Biogerontology Research Foundation (BGRF), a registered UK charity focusing on age-related diseases.
Since 2012, Dr. Zhavoronkov published over 120 peer-reviewed research papers and 2 books, including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy" (Palgrave Macmillan, 2013). From 2014 to 2018, he presented at over 200 academic and industry conferences.
Dr. Zhavoronkov serves on the editorial boards of some of the highest-impact journals in the field, including Aging, Aging Research Reviews, Frontiers in Genetics of Aging, Trends in Molecular Medicine, and chairs the Annual Aging Research for Drug Discovery Forum (6th annual in 2019) at the Basel Life. Dr. Zhavoronkov holds two bachelor degrees from Queen's University, a master's in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
Martin-Immanuel Bittner, MD DPhil
Arctoris
Martin-Immanuel Bittner is a Co-Founder and CEO of Arctoris, the world's first cloud lab dedicated to cancer drug discovery. Martin graduated as a medical doctor from the University of Freiburg in Germany, followed by his DPhil in Oncology as a Rhodes scholar at the University of Oxford. He has extensive research experience covering both clinical trials and preclinical drug discovery and is an active member of several leading cancer research organisations, including AACR, EACR, ESTRO and EORTC. In recognition of his research achievements, he was elected a member of the Young Academy of the German National Academy of Sciences in 2018.
Tyler Golato
Molecule.To
Tyler Golato, Scientific Lead at Molecule, is a biochemist, molecular biologist, and entrepreneur from the United States with a background in experimental therapeutics and biogerontology. He graduated from Stockton University before embarking on research fellowships at Columbia University and later, The National Institute of Aging. Tyler has developed novel therapeutics for treating several types of cancer, created new ways of measuring the DNA damage and repair response, and contributed to new theories around several rare genetic diseases.
Reason
Repair Biotechnologies
Reason is co-founder and CEO of Repair Biotechnologies, a biotech startup working on means of rejuvenation of the thymus and reversal of atherosclerosis. He is the founder and writer of Fight Aging!, which has been a leading voice in the longevity biotechnology and patient advocacy communities for more than fifteen years. Reason is also an active angel investor in the rejuvenation biotechnology space, and has for many years led and aided non-profit fundraising for academic research into rejuvenation via repair of molecular damage.
Michael Petr
The University of Copenhagen
Michael Petr holds a bachelor degree in Biomedical Engineering from North Carolina State University, USA. During college, he worked in United Therapeutics and GSK. After his bachelors, he was a research fellow in Rafael de Cabo's lab at the National Institute on Aging in Baltimore, MD where he comprehensively phenotyped aging mice in vivo with an array of preclinical imaging, computer vision and metabolic readouts. Currently he is a PhD candidate in Morten Scheibye-Knudsen's lab at the Center for Healthy Aging, University of Copenhagen studying the mechanism of interventions for aging and developing automated phenotyping technologies. His work attempts to bridge automation tech to comprehensive phenotyping of models orgnanisms for rapid readout of aging effects. Outside of his research Michael is active with Engineers Without Borders.
Andrei Gudkov
Roswell Park Comprehensive Cancer Center
Andrei Gudkov, Ph.D., Dr.Sci., Professor of Oncology, Sr. Vice President for Research Technology and Innovation and Chair of the Department of Cell Stress Biology of Roswell Park Comprehensive Cancer Center (Buffalo, NY). He graduated from Moscow State University and received his academic degrees working at the National Cancer Center in Moscow, former USSR. In 1990 he moved to the US to join Department of Genetics at the University of Illinois at Chicago. In 2001 he became Chair of the Department of Molecular Genetics at Cleveland Clinic and Professor of Biochemistry of Case Western Reserve University in Cleveland, OH. In 2007 he moved his research operations to Buffalo, New York, to take his current position at Roswell Park. He founded biotech companies Cleveland Biolabs, Incuron, Everon Biosciences, Oncotartis and Genome Protection that develop anticancer, antiaging and biodefense drugs. His interests have spanned through multiple areas of biomedical research including endogenous viruses, functional genomics, drug discovery, p53, inflammation, radiation biology and aging.
Alexey Moskalev
Engelhardt Institute of Molecular Biology
Prof. Alexey Moskalev is a Corresponding member of Russian Academy of Sciences, Doctor of Biology, the Head of the Laboratory of Geroprptective and Radioprotective Technologies in the Institute of Biology of Komi Scientific Centre of the Ural Branch of the Russian Academy of Sciences, the Head of the Department of Ecology of the Syktyvkar State University named after Pitirim Sorokin, the Head of the Laboratory of Genetics of Aging and Longevity in the Moscow Institute of Physics and Technology.


Morten Scheibye-Knudsen
The University of Copenhagen
Morten Scheibye-Knudsen is Associate Professor and group leader at the Center for Healthy Aging, University of Copenhagen, Denmark. Besides his research activity, he has been committed to educational programs and his online companies Mitodb.com and Forsøgsperson.dk. The latter has grown to become the largest single provider of study participants in Denmark. Morten Scheibye-Knudsen earned his MD in 2007 and his PhD in 2016 from the University of Copenhagen. After graduation, he worked as physician at Slagelse Hospital and at Nuuk Medical Clinic in Greenland. In 2008, he became a Postdoctoral Fellow at the National Institute on Aging at the NIH in Baltimore, Maryland. His work focused on the cross-talk between DNA repair and mitochondrial function in aging and has been honored by a number of competitive awards. In 2015 he was recruited to start his own research group at the University of Copenhagen, where his research group aims to understand the cellular and organismal consequences of DNA damage in the context of aging. With the ultimate goal to modulate and perhaps treat aging and age-related diseases, allowing everyone to live healthier and longer lives.
Anastasia Georgievskaya
Haut.AI
Anastasia Georgievskaya is the Co-founder and CEO of Haut.AI, an IT company developing AI-powered computer vision algorithms for skincare and skin health applications. The big goal of Haut.AI is to help people achieve the best skin look by using imaging data, to allow non-specialists in AI to introduce it to daily operations, and in general, help their clients experience healthy aging. Anastasia has 3 years' experience of integrating AI and computer vision algorithms into consumer companies' technology stacks. She has two degrees in bioengineering and biophysics.

Cecile Cai
36Kr
Cecile Cai is the senior analyst of 36Kr. 36Kr is a primary market information platform mainly focuses on Chinese market. During her tenure, Cecile identifies investments and performs research about healthcare market, and sets up a strong connection with top-tier VC and startups. Before this role, Cecile was the reporter of China Central Television and volunteer of United Nations. Cecile holds a master's degree in media and communications from the London School of Economics and Political Science.
Dmitry Kaminskiy
Deep Knowledge Ventures
Dmitry Kaminskiy is an innovative entrepreneur and investor active in the fields of Longevity, Precision Medicine, and Artificial Intelligence. He is co-founder and managing partner at Deep Knowledge Ventures, a data-science driven investment fund focused on DeepTech, renowned for its use of sophisticated analytical systems for investment target identification and due-diligence.

He is a frequent speaker on AI and Longevity, including events organized in London by The Economist "Aging Societies and The Business of Longevity", Financial Times "Smart Machines vs Smart People", Financial Times "Global Pharmaceutical and Biotechnology Conference", the "Precision Medicine World Conference" in Silicon Valleyas well as others at Oxford and Cambridge Universities.

In addition to his business experience, Dmitry is involved in several scientific endeavours. He strongly believes that humans should live longer healthier lives. He has a major interest in anti-aging and healthy longevity which is reflected in his business, research and public activities.
Martin Borch Jensen
Gordian Biotechnology
Martin Borch Jensen is co-founder and CSO of Gordian Biotechnology, a drug discovery company using high-throughput screening in vivo, to identify therapeutics for diseases of aging. Prior to Gordian he was a K99 fellow at the Buck Institute for Research on Aging, studying inter-organ signaling pathways contributing to age-related diseases. His early postdoctoral work was focused on regulation of longevity by mitochondrial stress signals, while his graduate work, at the National Institute on Aging, Baltimore, centered on mitochondrial function and DNA repair in accelerated aging disorders. He also spends time communicating the field of aging biology to broader audiences. This includes seminars at Y combinator, VC funds and non-profits, a popular science book on intermittent fasting, as well as appearances in Danish national TV, radio and newspapers.
Alexander Tyshkovskiy, Ph.D
Harvard Medical School
Alexander received his Master's degree in bioengineering and bioinformatics from Moscow State University in 2013. Afterwards, he performed his PhD project in the laboratory of Dr. Vadim Gladyshev in Brigham & Women's Hospital, Boston, and obtained his PhD degree in Life Sciences from Skolkovo Institute of Science and Technology in 2018. Currently, he is a postdoc in the laboratory of Dr. Vadim Gladyshev. Alexander's main focus of research is implementation of methods of computational biology, machine learning and data analysis to identify molecular mechanisms associated with aging and longevity, and utilize them to discover new effective lifespan-extending interventions.
Patrick Burgermeister
Kizoo Technology Capital
Patrick Burgermeister recently joined Kizoo coming from the venture capital group BioMedPartners where he was one of the partners. His experience in the industry encompasses both banking (as a senior analyst for pharma/biotech) as well as pharma (as a senior portfolio manager at Novartis). Patrick supported various biotech companies as a director on their boards, was a successful business developer for early-stage biotech companies and led collaboration and licensing deals with public and private companies. He headed business development at several companies including Apeiron Biologics and BioVersys. Patrick holds a Master's degree in molecular biology from the University of Basel, an MBA from the University St. Gallen and a degree as a Chartered Financial Analyst (CFA).
Jerome N. Feige, Ph.D
Nestle Research, EPFL Innovation Park
School of Life Sciences, Ecole Polytechnique Federale de Lausanne (EPFL), Lausanne, Switzerland
Michael Antonov
Longevity Investor / Co-founder Oculus
With a long history in game software industry, Michael was a co-founder and Chief Software Architect at Oculus, helping bring consumer Virtual Reality into the world. Over the last couple of years he's developed an active interest in life sciences, supporting health and longevity projects and startups.